25 July 2016 - The Institute for Clinical and Economic Review has released a final evidence report and meeting summary titled Diabetes Prevention Programs: Comparative Clinical Effectiveness and Value.
The final report reviews the comparative clinical effectiveness and value of CDC-recognized diabetes prevention programs and provides an in-depth review of the policy landscape for these interventions. The report includes a summary of votes taken during a public meeting of one of ICER's core programs, the California Technology Assessment Forum, as well as key policy recommendations stemming from discussion with a panel of experts during the meeting.
A key goal of ICER's reports is to ensure that patients, providers, insurers, and policymakers have the information they need to support efforts to improve the quality and value of care. The final report is accompanied by an action guide, which highlights the report's policy recommendations and provides external resources to support their implementation.